医药行业周报:JPM2026:海外药企战略转型与技术突破 进入价值兑现关键期

中信建投证券
Feb 01

核心观点:2026年JPM大会凸显海外药企在专利悬崖压力下加速战略转型与技术兑现。跨国药企通过大规模BD及并购平滑重磅产品专利到期冲击,默沙东规划700亿美元新产品组合,BMS完成300亿美元交易,阿斯利康目标2030年800亿美元营收。收并购依旧是各家跨国药企重要战略方向之一,跨国药企收并购与BD规划的核心逻辑是“应对专利悬崖+聚焦高确定性+技术平台补强”,同时绑定AI与前沿技术平台。2026-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10